OncoMatch

OncoMatch/Clinical Trials/NCT06823427

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

Is NCT06823427 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including 9MW2821 and Toripalimab (JS001 ) for urothelial carcinoma.

Phase 2RecruitingMabwell (Shanghai) Bioscience Co., Ltd.NCT06823427Data as of May 2026

Treatment: 9MW2821 · Toripalimab (JS001 )This study will compare the efficacy of 9MW2821+toripalimab versus 9MW2821 monotherapy in locally advanced or metastatic urothelial carcinoma patients who have not received any systemic treatment in the metastatic or advanced setting.

Check if I qualify

Extracted eligibility criteria

Cancer type

Urothelial Carcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: anti-PD-1 therapy

Have received prior treatment with anti-PD-1, anti-PD-L1/PD-L2 or anti-CTLA-4 therapies

Cannot have received: anti-PD-L1 therapy

Have received prior treatment with anti-PD-1, anti-PD-L1/PD-L2 or anti-CTLA-4 therapies

Cannot have received: anti-PD-L2 therapy

Have received prior treatment with anti-PD-1, anti-PD-L1/PD-L2 or anti-CTLA-4 therapies

Cannot have received: anti-CTLA-4 therapy

Have received prior treatment with anti-PD-1, anti-PD-L1/PD-L2 or anti-CTLA-4 therapies

Cannot have received: Nectin-4 targeted therapy

Have received prior treatment with Nectin-4 targeted therapy or ADC with MMAE as payload

Cannot have received: antibody-drug conjugate

Exception: ADC with MMAE as payload

Have received prior treatment with Nectin-4 targeted therapy or ADC with MMAE as payload

Cannot have received: allogeneic hematological stem cell transplantation

Have received allogeneic hematological stem cell transplantation or solid organ transplant

Cannot have received: solid organ transplant

Have received allogeneic hematological stem cell transplantation or solid organ transplant

Lab requirements

Blood counts

Appropriate hematological functions

Kidney function

Appropriate organ functions

Liver function

Appropriate organ functions

Appropriate hematological and organ functions

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify